

Ahwon Jeong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8202336/publications.pdf>

Version: 2024-02-01

8
papers

210
citations

1478505

6
h-index

1588992

8
g-index

8
all docs

8
docs citations

8
times ranked

355
citing authors

#	ARTICLE	IF	CITATIONS
1	Natural Killer Cell IFN γ Secretion is Profoundly Suppressed Following Colorectal Cancer Surgery. <i>Annals of Surgical Oncology</i> , 2018, 25, 3747-3754.	1.5	68
2	A randomized, double-blind, window of opportunity trial evaluating the effects of chloroquine in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 327-335.	2.5	51
3	A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2021, 142, 132-140.	2.8	42
4	Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review. <i>Supportive Care in Cancer</i> , 2021, 29, 925-943.	2.2	28
5	Randomized window of opportunity trial evaluating high-dose vitamin D in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 347-356.	2.5	9
6	Health Outcomes of Immigrants in Nursing Homes: A Population-Based Retrospective Cohort Study in Ontario, Canada. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 740-746.e5.	2.5	8
7	Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer. <i>Current Oncology</i> , 2021, 28, 1847-1856.	2.2	3
8	Efficacy and toxicity of extending bone modifying agents beyond two years for bone metastases in breast or castrate-resistant prostate cancer patients: A systematic review.. <i>Journal of Clinical Oncology</i> , 2020, 38, e24083-e24083.	1.6	1